

# Graham S Cooke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/705954/publications.pdf>

Version: 2024-02-01

204  
papers

18,474  
citations

28274  
55  
h-index

15266  
126  
g-index

255  
all docs

255  
docs citations

255  
times ranked

32026  
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver disease: at the heart of public health challenges for Europe in the 21st century. <i>Lancet</i> , The, 2022, 399, 9-10.	13.7	1
2	SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 355-366.	10.7	39
3	Antiviral metabolite 3'-deoxy-4'-didehydro-cytidine is detectable in serum and identifies acute viral infections including COVID-19. <i>Med</i> , 2022, 3, 204-215.e6.	4.4	12
4	Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. <i>Journal of Virological Methods</i> , 2022, 302, 114475.	2.1	8
5	Rapid increase in Omicron infections in England during December 2021: REACT-1 study. <i>Science</i> , 2022, 375, 1406-1411.	12.6	99
6	Simple, sensitive, specific self-sampling assay secures SARS-CoV-2 antibody signals in sero-prevalence and post-vaccine studies. <i>Scientific Reports</i> , 2022, 12, 1885.	3.3	3
7	Perceptions on the Use of Wearable Sensors and Continuous Monitoring in Surgical Patients: Interview Study Among Surgical Staff. <i>JMIR Formative Research</i> , 2022, 6, e27866.	1.4	3
8	Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO. <i>BMJ Open</i> , 2022, 12, e053349.	1.9	12
9	Namulumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 255-266.	10.7	32
10	Population antibody responses following COVID-19 vaccination in 212,102 individuals. <i>Nature Communications</i> , 2022, 13, 907.	12.8	94
11	A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination. <i>Seminars in Liver Disease</i> , 2022, 42, 159-172.	3.6	14
12	Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. <i>The Lancet Digital Health</i> , 2022, 4, e220-e234.	12.3	20
13	Persistent COVID-19 symptoms in a community study of 606,434 people in England. <i>Nature Communications</i> , 2022, 13, 1957.	12.8	198
14	Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study. <i>EClinicalMedicine</i> , 2022, 48, 101419.	7.1	8
15	Seroprevalence of Hepatitis B, C and D in Vietnam: A systematic review and meta-analysis. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 24, 100468.	2.9	3
16	Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England. <i>Science</i> , 2022, 376, .	12.6	78
17	Engaging with HCV reinfection to advance microelimination. <i>Lancet HIV</i> , the, 2022, 9, e372-e374.	4.7	1
18	Appropriately smoothing prevalence data to inform estimates of growth rate and reproduction number. <i>Epidemics</i> , 2022, 40, 100604.	3.0	15

#	ARTICLE	IF	CITATIONS
19	Machine learning to support visual auditing of home-based lateral flow immunoassay self-test results for SARS-CoV-2 antibodies. <i>Communications Medicine</i> , 2022, 2, .	4.2	13
20	Clinical Characteristics and Predictors of Outcomes of Hospitalized Patients With Coronavirus Disease 2019 in a Multiethnic London National Health Service Trust: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e4047-e4057.	5.8	81
21	Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom?. <i>Clinical Infectious Diseases</i> , 2021, 72, 233-238.	5.8	45
22	Reply to Dudoignon et al. <i>Clinical Infectious Diseases</i> , 2021, 72, 906-908.	5.8	3
23	Factors associated with reattendance to emergency services following COVID-19 hospitalization. <i>Journal of Medical Virology</i> , 2021, 93, 1250-1252.	5.0	1
24	Usability and Acceptability of Home-based Self-testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies for Population Surveillance. <i>Clinical Infectious Diseases</i> , 2021, 72, e384-e393.	5.8	55
25	Changes in the hospital admission profile of COVID-19 positive patients at a central London trust. <i>Journal of Infection</i> , 2021, 82, 159-198.	3.3	2
26	The under-representation of BAME patients in the COVID-19 Recovery trial at a major London NHS Trust. <i>Journal of Infection</i> , 2021, 82, 84-123.	3.3	9
27	Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China. <i>PLoS ONE</i> , 2021, 16, e0245288.	2.5	5
28	SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. <i>Nature Communications</i> , 2021, 12, 905.	12.8	168
29	SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. <i>BMJ</i> , The, 2021, 372, n423.	6.0	56
30	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 699-711.	10.7	122
31	Decentralisation, integration, and task-shifting: tools to accelerate the elimination of hepatitis C. <i>The Lancet Global Health</i> , 2021, 9, e375-e376.	6.3	5
32	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. <i>Wellcome Open Research</i> , 2021, 6, 93.	1.8	1
33	Short-Term Wearable Sensors for In-Hospital Medical and Surgical Patients: Mixed Methods Analysis of Patient Perspectives. <i>JMIR Perioperative Medicine</i> , 2021, 4, e18836.	1.0	10
34	Resurgence of SARS-CoV-2: Detection by community viral surveillance. <i>Science</i> , 2021, 372, 990-995.	12.6	91
35	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 349-359.	10.7	161
36	Identification of hepatitis delta superinfection when investigating transaminitis in HIV/hepatitis B virus co-infection. <i>Aids</i> , 2021, 35, 1704-1706.	2.2	2

#	ARTICLE	IF	CITATIONS
37	Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. <i>Lancet Regional Health - Europe</i> , The, 2021, 4, 100098.	5.6	91
38	COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. <i>Infection</i> , 2021, 49, 889-905.	4.7	62
39	Changes in Emergency Department Activity and the First COVID-19 Lockdown: A Cross-sectional Study. <i>Western Journal of Emergency Medicine</i> , 2021, 22, 603-607.	1.1	17
40	High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab267.	0.9	6
41	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. <i>Wellcome Open Research</i> , 2021, 6, 93.	1.8	7
42	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 773-785.	10.7	78
43	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. <i>Lancet</i> , The, 2021, 398, 223-237.	13.7	110
44	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. <i>Nature Communications</i> , 2021, 12, 4450.	12.8	67
45	Cuts to UK official development assistance budget jeopardise global viral hepatitis elimination goals. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 527-528.	8.1	0
46	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e498-e506.	3.9	58
47	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. <i>Lancet Microbe</i> , The, 2021, 2, e354-e365.	7.3	216
48	Progress towards antibiotic use targets in eight high-income countries. <i>Bulletin of the World Health Organization</i> , 2021, 99, 550-561.	3.3	8
49	Discovery and validation of a three-gene signature to distinguish COVID-19 and other viral infections in emergency infectious disease presentations: a case-control and observational cohort study. <i>Lancet Microbe</i> , The, 2021, 2, e594-e603.	7.3	17
50	Predictive symptoms for COVID-19 in the community: REACT-1 study of over 1 million people. <i>PLoS Medicine</i> , 2021, 18, e1003777.	8.4	72
51	Global access to affordable direct oral anticoagulants. <i>Bulletin of the World Health Organization</i> , 2021, 99, 653-660.	3.3	5
52	A prenylated dsRNA sensor protects against severe COVID-19. <i>Science</i> , 2021, 374, eabj3624.	12.6	124
53	The impact of the COVID-19 pandemic on patterns of attendance at emergency departments in two large London hospitals: an observational study. <i>BMC Health Services Research</i> , 2021, 21, 1008.	2.2	15
54	Comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1429-1440.	9.1	18

#	ARTICLE	IF	CITATIONS
55	Association between intrahospital transfer and hospital-acquired infection in the elderly: a retrospective case-control study in a UK hospital network. <i>BMJ Quality and Safety</i> , 2021, 30, 457-466.	3.7	16
56	Acceptability, Usability, and Performance of Lateral Flow Immunoassay Tests for Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: REACT-2 Study of Self-Testing in Nonhealthcare Key Workers. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab496.	0.9	12
57	Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-90.	0.7	0
58	Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. <i>Science</i> , 2021, 374, eabl9551.	12.6	111
59	Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial. <i>Blood</i> , 2021, 138, 4200-4200.	1.4	0
60	Global surveillance, research, and collaboration needed to improve understanding and management of long COVID. <i>Lancet</i> , The, 2021, 398, 2057-2059.	13.7	19
61	Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection. <i>Hepatology</i> , 2020, 72, 7-18.	7.3	24
62	Evaluating a digital sepsis alert in a London multisite hospital network: a natural experiment using electronic health record data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 274-283.	4.4	21
63	Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2020, 23, 180-190.	0.3	1
64	Launch of the Coalition for Global Hepatitis Elimination: a recommendation of the Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 8-10.	8.1	4
65	Interventions to reduce acute hepatitis C virus in HIV-positive MSM. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 1-9.	3.1	1
66	A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK. <i>Journal of Infection</i> , 2020, 80, 38-41.	3.3	8
67	Impact of virus subtype and host IFNL4 genotype on large-scale RNA structure formation in the genome of hepatitis C virus. <i>Rna</i> , 2020, 26, 1541-1556.	3.5	7
68	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. <i>PLoS ONE</i> , 2020, 15, e0235715.	2.5	12
69	Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 948-953.	8.1	24
70	Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. <i>Thorax</i> , 2020, 75, 1082-1088.	5.6	133
71	Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. <i>Lancet Microbe</i> , The, 2020, 1, e300-e307.	7.3	92
72	Decline in HCV incidence in HIV positive MSM - progress to HCV micro-elimination in the UK?. <i>Journal of Hepatology</i> , 2020, 73, S32-S33.	3.7	0

#	ARTICLE	IF	CITATIONS
73	Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. <i>Lancet Microbe</i> , The, 2020, 1, e245-e253.	7.3	441
74	From stagnation to elimination: tracking hepatitis C elimination policy implementation in Europe in partnership with patient organizations. <i>Journal of Hepatology</i> , 2020, 73, S793-S794.	3.7	0
75	Do countries have the right policies to eliminate viral hepatitis B and C: a secondary analysis of the Lancet GastroHep viral hepatitis commission. <i>Journal of Hepatology</i> , 2020, 73, S811.	3.7	2
76	Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. <i>Clinical Infectious Diseases</i> , 2020, 71, 2459-2468.	5.8	1,006
77	The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam. <i>Trials</i> , 2020, 21, 413.	1.6	5
78	<i>Strongyloides stercoralis</i> infection in HIV-positive men who have sex with men. <i>International Journal of STD and AIDS</i> , 2020, 31, 398-401.	1.1	4
79	Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England. <i>Journal of Viral Hepatitis</i> , 2020, 27, 721-730.	2.0	16
80	Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease. <i>Journal of Infection</i> , 2020, 81, 647-679.	3.3	1
81	2019 Community-acquired Pneumonia Treatment Guidelines: There Is a Need for a Change toward More Parsimonious Antibiotic Use. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1315-1316.	5.6	12
82	REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. <i>Wellcome Open Research</i> , 2020, 5, 200.	1.8	55
83	National Institute for Health Research Health Informatics Collaborative: development of a pipeline to collate electronic clinical data for viral hepatitis research. <i>BMJ Health and Care Informatics</i> , 2020, 27, e100145.	3.0	14
84	Rational use of SARS-CoV-2 polymerase chain reaction tests within institutions caring for the vulnerable. <i>F1000Research</i> , 2020, 9, 671.	1.6	8
85	REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. <i>Wellcome Open Research</i> , 2020, 5, 200.	1.8	93
86	Predictors of recurrence, early treatment failure and death from <i>Staphylococcus aureus</i> bacteraemia: Observational analyses within the ARREST trial. <i>Journal of Infection</i> , 2019, 79, 332-340.	3.3	11
87	Pricing viral hepatitis as part of universal health coverage. <i>The Lancet Global Health</i> , 2019, 7, e1148-e1149.	6.3	0
88	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. <i>Clinical Infectious Diseases</i> , 2019, 69, 2218-2227.	5.8	52
89	Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. <i>Journal of Infection</i> , 2019, 79, 503-512.	3.3	23
90	Responses to Quadrivalent Influenza Vaccine Reveal Distinct Circulating CD4+CXCR5+ T Cell Subsets in Men Living with HIV. <i>Scientific Reports</i> , 2019, 9, 15650.	3.3	11

#	ARTICLE	IF	CITATIONS
91	Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis. <i>The Lancet Global Health</i> , 2019, 7, e1189-e1196.	6.3	24
92	THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection. <i>Journal of Hepatology</i> , 2019, 70, e231.	3.7	4
93	Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. <i>Lancet, The</i> , 2019, 393, 1319-1329.	13.7	212
94	Oral versus Intravenous Antibiotics for Bone and Joint Infection. <i>New England Journal of Medicine</i> , 2019, 380, 425-436.	27.0	548
95	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2019, 22, 693-703.	0.3	13
96	Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam. <i>PLoS ONE</i> , 2019, 14, e0212734.	2.5	14
97	Encouraging AWARe-ness and discouraging inappropriate antibiotic use—the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. <i>Lancet Infectious Diseases, The</i> , 2019, 19, 1278-1280.	9.1	106
98	Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV mono-infection independently of the gut microbiome and bacterial translocation. <i>Aids</i> , 2019, 33, 805-814.	2.2	20
99	Spleen stiffness measurements using point shear wave elastography detects noncirrhotic portal hypertension in human immunodeficiency virus. <i>Medicine (United States)</i> , 2019, 98, e17961.	1.0	8
100	Wearable sensors to improve detection of patient deterioration. <i>Expert Review of Medical Devices</i> , 2019, 16, 145-154.	2.8	70
101	Clinical utility of existing and second-generation interferon- $\gamma$ release assays for diagnostic evaluation of tuberculosis: an observational cohort study. <i>Lancet Infectious Diseases, The</i> , 2019, 19, 193-202.	9.1	47
102	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 135-184.	8.1	370
103	The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam. <i>Wellcome Open Research</i> , 2019, 4, 129.	1.8	4
104	Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. <i>Wellcome Open Research</i> , 2019, 4, 132.	1.8	21
105	Digital Alerting and Outcomes in Patients With Sepsis: Systematic Review and Meta-Analysis. <i>Journal of Medical Internet Research</i> , 2019, 21, e15166.	4.3	41
106	Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-92.	2.8	27
107	The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam. <i>Wellcome Open Research</i> , 2019, 4, 129.	1.8	4
108	Hepatitis in the traveller. <i>Medicine</i> , 2018, 46, 20-23.	0.4	3



#	ARTICLE	IF	CITATIONS
109	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. <i>Npj Vaccines</i> , 2018, 3, 49.	6.0	51
110	Cohort study protocol: Bioresource in Adult Infectious Diseases (BioAID). Wellcome Open Research, 2018, 3, 97.	1.8	6
111	Estimated generic prices for novel treatments for drug-resistant tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw522.	3.0	19
112	Scaling up HCV treatment to achieve WHO targets by 2030. <i>Tropical Medicine and International Health</i> , 2017, 22, 372-374.	2.3	5
113	Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. <i>Nature Genetics</i> , 2017, 49, 666-673.	21.4	129
114	Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008–2014. <i>Journal of Infection</i> , 2017, 74, 260-271.	3.3	15
115	Risk of Tuberculosis Infection and Disease for Health Care Workers: An Updated Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx137.	0.9	95
116	Impact of Point-of-Care Xpert MTB/RIF on Tuberculosis Treatment Initiation. A Cluster-randomized Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 901-910.	5.6	37
117	Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	37
118	Can Hepatitis C Virus Antigen Testing Replace Ribonucleic Acid Polymerase Chain Reaction Analysis for Detecting Hepatitis C Virus? A Systematic Review. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw252.	0.9	18
119	PD-1 Expression and Cytokine Secretion Profiles of Mycobacterium tuberculosis-Specific CD4+ T-Cell Subsets; Potential Correlates of Containment in HIV-TB Co-Infection. <i>PLoS ONE</i> , 2016, 11, e0146905.	2.5	31
120	The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. <i>Lancet</i> , The, 2016, 388, 1081-1088.	13.7	1,080
121	Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. <i>Clinical Infectious Diseases</i> , 2016, 62, 1072-1080.	5.8	122
122	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet</i> , The, 2016, 388, 1813-1850.	13.7	413
123	Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-infected patients with mild liver disease. <i>Journal of Viral Hepatitis</i> , 2016, 23, 123-129.	2.0	3
124	Genotype 4 and the global challenge of hepatitis C treatment. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 3-4.	8.1	1
125	Can routine genetic testing help to end TB transmission?. <i>Thorax</i> , 2016, 71, 681-682.	5.6	1
126	A new paradigm evaluating cost per cure of HCV infection in the UK. <i>Hepatology, Medicine and Policy</i> , 2016, 1, 2.	1.7	5



#	ARTICLE	IF	CITATIONS
127	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01<sub>B</sub>With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. <i>Journal of Infectious Diseases</i> , 2016, 214, 772-781.	4.0	96
128	Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 683-694.	5.8	262
129	HCV and HIV: shared challenges, shared solutions. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 755-756.	9.1	4
130	The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. <i>Gut</i> , 2016, 65, 1369-1376.	12.1	267
131	Might ART Adherence Estimates Be Improved by Combining Biomarker and Self-Report Data?. <i>PLoS ONE</i> , 2016, 11, e0167852.	2.5	8
132	Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. <i>Journal of Virus Eradication</i> , 2015, 1, 103-110.	0.5	28
133	Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. <i>Clinical Infectious Diseases</i> , 2015, 61, 730-740.	5.8	229
134	Diagnostics for resourceâ€limited settings in the era of interferonâ€free <scp>HCV</scp> therapy. <i>Journal of Viral Hepatitis</i> , 2015, 22, 459-460.	2.0	4
135	The Global Burden of Cancer 2013. <i>JAMA Oncology</i> , 2015, 1, 505.	7.1	2,269
136	Differences in antigenâ€specific CD4+ responses to opportunistic infections in HIV infection. <i>Immunity, Inflammation and Disease</i> , 2015, 3, 141-153.	2.7	11
137	A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1812-5.	3.0	2
138	Strength of recommendations in WHO guidelines using GRADE was associated with uptake in national policy. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 703-707.	5.0	28
139	Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 819-824.	9.1	107
140	Fatal Nosocomial MDR TB Identified through Routine Genetic Analysis and Whole-Genome Sequencing. <i>Emerging Infectious Diseases</i> , 2015, 21, 1082-1084.	4.3	12
141	Minimum target prices for production of directâ€acting antivirals and associated diagnostics to combat hepatitis C virus. <i>Hepatology</i> , 2015, 61, 1174-1182.	7.3	51
142	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990â€2013: quantifying the epidemiological transition. <i>Lancet</i> , The, 2015, 386, 2145-2191.	13.7	1,544
143	Global distribution and prevalence of hepatitis C virus genotypes. <i>Hepatology</i> , 2015, 61, 77-87.	7.3	1,293
144	Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. <i>Journal of Virus Eradication</i> , 2015, 1, 103-10.	0.5	16

#	ARTICLE	IF	CITATIONS
145	Low levels of HIV test coverage in clinical settings in the UK: a systematic review of adherence to 2008 guidelines. Sexually Transmitted Infections, 2014, 90, 119-124.	1.9	57
146	Impact of point-of-care CD4 testing on linkage to HIV care: a systematic review. Journal of the International AIDS Society, 2014, 17, 18809.	3.0	104
147	Systematic review and meta-analysis: Patient and programme impact of fixed-dose combination antiretroviral therapy. Tropical Medicine and International Health, 2014, 19, 501-513.	2.3	60
148	Hepatitis C can be cured globally, but at what cost?. Science, 2014, 345, 141-142.	12.6	60
149	Impact of a novel molecular TB diagnostic system in patients at high risk of TB mortality in rural South Africa (Uchwepheshe): study protocol for a cluster randomised trial. Trials, 2013, 14, 170.	1.6	6
150	Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2013, 68, 284-293.	3.0	116
151	Viral hepatitis and the global burden of disease: a need to regroup. Journal of Viral Hepatitis, 2013, 20, 600-601.	2.0	104
152	The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype. Aids, 2013, 27, 484-485.	2.2	2
153	Tracking the progress of HIV: the impact of point-of-care tests on antiretroviral therapy. Clinical Epidemiology, 2013, 5, 387.	3.0	24
154	Treatment Outcomes of Treatment-Naïve Hepatitis C Patients Co-Infected with HIV: A Systematic Review and Meta-Analysis of Observational Cohorts. PLoS ONE, 2013, 8, e55373.	2.5	30
155	Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort. World Journal of Gastroenterology, 2013, 19, 1602.	3.3	38
156	Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa. Journal of AIDS & Clinical Research, 2013, 01, .	0.5	11
157	Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bulletin of the World Health Organization, 2012, 90, 540-550.	3.3	56
158	A Comparison between Two Strategies for Monitoring Hepatic Function during Antituberculous Therapy. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 653-659.	5.6	44
159	Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/AIDS. Clinical Infectious Diseases, 2012, 54, 1465-1472.	5.8	71
160	Comparison of screening strategies to improve the diagnosis of latent tuberculosis infection in the HIV-positive population: a cohort study. BMJ Open, 2012, 2, e000762.	1.9	7
161	Technologies for global health. Lancet, The, 2012, 380, 507-535.	13.7	311
162	Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2012, 12, 449-456.	9.1	164

#	ARTICLE	IF	CITATIONS
163	Host Genetics and Susceptibility to Infection. , 2011, , 32-39.		1
164	International Spread of MDR TB from Tugela Ferry, South Africa. Emerging Infectious Diseases, 2011, 17, 2035-7.	4.3	22
165	Retention in HIV Care for Individuals Not Yet Eligible for Antiretroviral Therapy: Rural KwaZulu-Natal, South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e79-e86.	2.1	122
166	Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. Journal of Antimicrobial Chemotherapy, 2011, 66, 1815-1820.	3.0	80
167	Evaluation of Tuberculosis Diagnostics: Establishing an Evidence Base Around the Public Health Impact. Journal of Infectious Diseases, 2011, 204, S1187-S1195.	4.0	21
168	Acute renal failure due to immune reconstitution inflammatory interstitial nephritis in an HIV-positive patient. Aids, 2010, 24, 1788-1790.	2.2	10
169	Jaundice in the traveller. Medicine, 2010, 38, 14-17.	0.4	0
170	Population uptake of antiretroviral treatment through primary care in rural South Africa. BMC Public Health, 2010, 10, 585.	2.9	71
171	The tuberculosis challenge in a rural South African HIV programme. BMC Infectious Diseases, 2010, 10, 23.	2.9	44
172	Treatment of Cryptococcal Meningitis in KwaZulu-Natal, South Africa. PLoS ONE, 2010, 5, e8630.	2.5	24
173	Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes?. Bulletin of the World Health Organization, 2010, 88, 593-600.	3.3	104
174	Treatment for hepatitis B. BMJ: British Medical Journal, 2010, 340, b5429-b5429.	2.3	24
175	Need for Timely Paediatric HIV Treatment within Primary Health Care in Rural South Africa. PLoS ONE, 2009, 4, e7101.	2.5	10
176	Localized spatial clustering of HIV infections in a widely disseminated rural South African epidemic. International Journal of Epidemiology, 2009, 38, 1008-1016.	1.9	173
177	Hepatitis B treatment in resource poor settings: time for action. Tropical Medicine and International Health, 2009, 15, 2-4.	2.3	15
178	Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bulletin of the World Health Organization, 2009, 87, 754-762.	3.3	145
179	Early impact on adult mortality from a government art programme in rural kwazulu-natal. Journal of Infection, 2008, 56, 303-304.	3.3	1
180	HIV and hepatitis B co-infection in Africa. Lancet Infectious Diseases, The, 2008, 8, 210-211.	9.1	9

#	ARTICLE	IF	CITATIONS
181	Mapping of a Novel Susceptibility Locus Suggests a Role for MC3R and CTSZ in Human Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 203-207.	5.6	83
182	Cluster of Falciparum Malaria Cases in UK Airport. Emerging Infectious Diseases, 2008, 14, 1284-1286.	4.3	13
183	Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study. PLoS ONE, 2008, 3, e3173.	2.5	42
184	Evolution of adult antiretroviral therapy for programmatic delivery in Africa and the potential role for new therapeutic approaches. Therapy: Open Access in Clinical Medicine, 2007, 4, 767-774.	0.2	1
185	Response to Mallet et al., "Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients". Aids, 2007, 21, 1494-1495.	2.2	25
186	Improving the treatment of hepatitis C infection in the UK. Expert Opinion on Pharmacotherapy, 2007, 8, 183-191.	1.8	1
187	Impact on and use of an inner-city London Infectious Diseases Department by international migrants: a questionnaire survey. BMC Health Services Research, 2007, 7, 113.	2.2	17
188	Polymorphism within the Interferon- $\gamma$ /Receptor Complex Is Associated with Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 339-343.	5.6	111
189	F-18 FDG PET in the Diagnosis and Monitoring of Salmonella Vertebral Osteomyelitis: A Comparison With MRI. Clinical Nuclear Medicine, 2006, 31, 437-440.	1.3	10
190	Deep-Seated Resistance in Relapsed Paratyphoid Fever. Clinical Infectious Diseases, 2006, 42, e92-e94.	5.8	4
191	A Polymorphism That Reduces RANTES Expression Is Associated with Protection from Death in HIV-Seropositive Ugandans with Advanced Disease. Journal of Infectious Diseases, 2006, 194, 666-669.	4.0	27
192	Association between tuberculosis and a polymorphic NF- $\kappa$ B binding site in the interferon $\gamma$ gene. Lancet, The, 2003, 361, 1871-1872.	13.7	216
193	Identification of Susceptibility Genes for Tuberculosis in Southern and West Africans Using Family-Based Linkage Analysis and Linkage Disequilibrium Mapping. Clinical Science, 2003, 104, 56P-56P.	0.0	0
194	Association of Fc $\gamma$ receptor IIa (CD32) polymorphism with severe malaria in West Africa. American Journal of Tropical Medicine and Hygiene, 2003, 69, 565-8.	1.4	39
195	Genetics of susceptibility to human infectious disease. Nature Reviews Genetics, 2001, 2, 967-977.	16.3	447
196	In vivo negative regulation of SARS-CoV-2 receptor, ACE2, by interferons and its genetic control. Wellcome Open Research, 0, 6, 47.	1.8	2
197	Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. Wellcome Open Research, 0, 6, 203.	1.8	0
198	Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and Utility. SSRN Electronic Journal, 0, , .	0.4	3

#	ARTICLE	IF	CITATIONS
199	Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. Wellcome Open Research, 0, 6, 203.	1.8	0
200	Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK. Wellcome Open Research, 0, 7, 51.	1.8	0
201	Characterising the persistence of RT-PCR positivity and incidence in a community survey of SARS-CoV-2. Wellcome Open Research, 0, 7, 102.	1.8	7
202	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. Wellcome Open Research, 0, 6, 358.	1.8	5
203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. Wellcome Open Research, 0, 6, 358.	1.8	2
204	Cohort Profile: The National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) research dataset. International Journal of Epidemiology, 0, , .	1.9	2